These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 31976485)

  • 21.
    Andersson EI; Brück O; Braun T; Mannisto S; Saikko L; Lagström S; Ellonen P; Leppä S; Herling M; Kovanen PE; Mustjoki S
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32188095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Recurrent
    Kieslinger M; Swoboda A; Kramer N; Freund P; Pratscher B; Neubauer HA; Steinborn R; Wolfesberger B; Fuchs-Baumgartinger A; Moriggl R; Burgener IA
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
    Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
    PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.
    Küçük C; Jiang B; Hu X; Zhang W; Chan JK; Xiao W; Lack N; Alkan C; Williams JC; Avery KN; Kavak P; Scuto A; Sen E; Gaulard P; Staudt L; Iqbal J; Zhang W; Cornish A; Gong Q; Yang Q; Sun H; d'Amore F; Leppä S; Liu W; Fu K; de Leval L; McKeithan T; Chan WC
    Nat Commun; 2015 Jan; 6():6025. PubMed ID: 25586472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STAT5BN642H is a driver mutation for T cell neoplasia.
    Pham HTT; Maurer B; Prchal-Murphy M; Grausenburger R; Grundschober E; Javaheri T; Nivarthi H; Boersma A; Kolbe T; Elabd M; Halbritter F; Pencik J; Kazemi Z; Grebien F; Hengstschläger M; Kenner L; Kubicek S; Farlik M; Bock C; Valent P; Müller M; Rülicke T; Sexl V; Moriggl R
    J Clin Invest; 2018 Jan; 128(1):387-401. PubMed ID: 29200404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
    Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
    Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
    Liu Y; Easton J; Shao Y; Maciaszek J; Wang Z; Wilkinson MR; McCastlain K; Edmonson M; Pounds SB; Shi L; Zhou X; Ma X; Sioson E; Li Y; Rusch M; Gupta P; Pei D; Cheng C; Smith MA; Auvil JG; Gerhard DS; Relling MV; Winick NJ; Carroll AJ; Heerema NA; Raetz E; Devidas M; Willman CL; Harvey RC; Carroll WL; Dunsmore KP; Winter SS; Wood BL; Sorrentino BP; Downing JR; Loh ML; Hunger SP; Zhang J; Mullighan CG
    Nat Genet; 2017 Aug; 49(8):1211-1218. PubMed ID: 28671688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SynergyFinder: a web application for analyzing drug combination dose-response matrix data.
    Ianevski A; He L; Aittokallio T; Tang J
    Bioinformatics; 2017 Aug; 33(15):2413-2415. PubMed ID: 28379339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model.
    Yadav B; Wennerberg K; Aittokallio T; Tang J
    Comput Struct Biotechnol J; 2015; 13():504-13. PubMed ID: 26949479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
    Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
    J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.
    Vicente C; Schwab C; Broux M; Geerdens E; Degryse S; Demeyer S; Lahortiga I; Elliott A; Chilton L; La Starza R; Mecucci C; Vandenberghe P; Goulden N; Vora A; Moorman AV; Soulier J; Harrison CJ; Clappier E; Cools J
    Haematologica; 2015 Oct; 100(10):1301-10. PubMed ID: 26206799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
    Vannucchi AM; Kantarjian HM; Kiladjian JJ; Gotlib J; Cervantes F; Mesa RA; Sarlis NJ; Peng W; Sandor V; Gopalakrishna P; Hmissi A; Stalbovskaya V; Gupta V; Harrison C; Verstovsek S;
    Haematologica; 2015 Sep; 100(9):1139-45. PubMed ID: 26069290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
    Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
    Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
    Vannucchi AM; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Mesa R; He S; Jones MM; Garrett W; Li J; Pirron U; Habr D; Verstovsek S
    N Engl J Med; 2015 Jan; 372(5):426-35. PubMed ID: 25629741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
    Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
    Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse.
    Bandapalli OR; Schuessele S; Kunz JB; Rausch T; Stütz AM; Tal N; Geron I; Gershman N; Izraeli S; Eilers J; Vaezipour N; Kirschner-Schwabe R; Hof J; von Stackelberg A; Schrappe M; Stanulla M; Zimmermann M; Koehler R; Avigad S; Handgretinger R; Frismantas V; Bourquin JP; Bornhauser B; Korbel JO; Muckenthaler MU; Kulozik AE
    Haematologica; 2014 Oct; 99(10):e188-92. PubMed ID: 24972766
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.
    Kontro M; Kuusanmäki H; Eldfors S; Burmeister T; Andersson EI; Bruserud O; Brümmendorf TH; Edgren H; Gjertsen BT; Itälä-Remes M; Lagström S; Lohi O; Lundán T; Martí JM; Majumder MM; Parsons A; Pemovska T; Rajala H; Vettenranta K; Kallioniemi O; Mustjoki S; Porkka K; Heckman CA
    Leukemia; 2014 Aug; 28(8):1738-42. PubMed ID: 24573384
    [No Abstract]   [Full Text] [Related]  

  • 38. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
    Zhang J; Ding L; Holmfeldt L; Wu G; Heatley SL; Payne-Turner D; Easton J; Chen X; Wang J; Rusch M; Lu C; Chen SC; Wei L; Collins-Underwood JR; Ma J; Roberts KG; Pounds SB; Ulyanov A; Becksfort J; Gupta P; Huether R; Kriwacki RW; Parker M; McGoldrick DJ; Zhao D; Alford D; Espy S; Bobba KC; Song G; Pei D; Cheng C; Roberts S; Barbato MI; Campana D; Coustan-Smith E; Shurtleff SA; Raimondi SC; Kleppe M; Cools J; Shimano KA; Hermiston ML; Doulatov S; Eppert K; Laurenti E; Notta F; Dick JE; Basso G; Hunger SP; Loh ML; Devidas M; Wood B; Winter S; Dunsmore KP; Fulton RS; Fulton LL; Hong X; Harris CC; Dooling DJ; Ochoa K; Johnson KJ; Obenauer JC; Evans WE; Pui CH; Naeve CW; Ley TJ; Mardis ER; Wilson RK; Downing JR; Mullighan CG
    Nature; 2012 Jan; 481(7380):157-63. PubMed ID: 22237106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors.
    Govaerts I; Jacobs K; Vandepoel R; Cools J
    Hemasphere; 2019 Dec; 3(6):e313. PubMed ID: 31976485
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.